What’s New in Psoriatic Arthritis?

As reported by Martin and colleagues, the study team performed Achilles elastography (EL-AQ) in 57 PsA patients with or without Achilles tendon involvement using ultrasound before and after controlled exercise (20 minutes on a stationary bicycle at medium resistance). As a measure of tendon properties, the MASEI (Madrid Sonographic Enthesis Score) was calculated.

The results showed the EL-AQ can discriminate between patients and controls and that changes can occur with or without clinical Achilles tendon involvement.

These are interesting findings that extend the usual use of ultrasonography to assess changes in the mechanical properties of tendons; future studies will be needed to determine the extent to which these changes reflect inflammation and, therefore, may be modified by therapy.

David S. Pisetsky, MD, PhD, is a professor of medicine and integrative immunobiology at Duke University School of Medicine, Durham, N.C., and a staff rheumatologist at the Durham VA Medical Center. He also served as the first physician editor of The Rheumatologist.

References

1. Orbai A, Wang H, Grecu M, et al. Anti-peptidylarginine deiminase-2 (anti-PAD2) autoantibodies in psoriatic arthritis [abstract 0529]. Arthritis Rheumatol. 2025;77(suppl 9).
2. Tskitishvili R, Hussein A, Tskhakaia I, et al. Risk of inflammatory bowel disease in psoriatic arthritis patients treated with IL-17 inhibitors [abstract 1183]. Arthritis Rheumatol. 2025;77(suppl 9).
3. Mehta P, Yang M, Carrizo Abarza V, et al. Understanding the impact of overweight and obesity on treatment response in psoriatic arthritis: Results from a longitudinal cohort study [abstract 2691]. Arthritis Rheumatol. 2025;7(suppl 9).
4. Tsibadze N, Tskhakaia I, Tan I. Mortality and major adverse cardiac events (MACE) with GLP-1 receptor agonists in psoriatic arthritis [abstract 0849]. Arthritis Rheumatol. 2025;7(suppl 9).
5. Ritchlin C, Rangel-Moreno J, Rangel-Garcia A, et al. Axial psoriatic arthritis is phenocopied in a humanized mouse model [abstract 1753]. Arthritis Rheumatol. 2025;7(suppl 9).
6. Raimondo M, Mohammadian H, Angeli M, et al. Skin-to-joint immune cell migration and synovial reprogramming in psoriatic arthritis onset [abstract 1757]. Arthritis Rheumatol. 2025;7(suppl 9).
7. Vladimirova N, Hadsbjerg A, Krabbe S, et al. Unveiling sacroiliac joint involvement in psoriatic arthritis: MRI, radiographic, and clinical insights from 581 European routine care patients [abstract 0543]. Arthritis Rheumatol. 2025;7(suppl 9).
8. Almansouri A, Li J, Alhadri A, et al. The incidence rate and risk factors of arrhythmias in patients with psoriatic arthritis [abstract 0522]. Arthritis Rheumatol. 2025;7(suppl 9).
9. Wiebe E, Huscher D, Boyadzhieva Z, et al. Impact of Janus Kinase inhibitors on bone mineral density and microarchitecture in rheumatoid and psoriatic arthritis: Insights from a real-world cohort [abstract 0343]. Arthritis Rheumatol. 2025;7(suppl 9).
10. Mikolajczak L, Kuhn H, Harrold L, Reed G. Impact of psoriatic arthritis disease activity and fatigue on subjective cognitive decline (‘brainfog’) [abstract 1421]. Arthritis Rheumatol. 2025;7(suppl 9).
11. Eder L, Li X, Koppikar S, et al. The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis [abstract  1714]. Arthritis Rheumatol. 2025;77(suppl 9).
12. Martin Martin I, San Jose Mendez C, Jimenez Barrios S, et al. Role of achilles elastography in differentiating patients with early psoriatic arthritis [abstract 0107]. Arthritis Rheumatol. 2025;7(suppl 9).